Share story
Science Products

Merck KGaA agrees to buy Silence Therapeutics for approximately $1.3bn

Merck to acquire Silence Therapeutics in $1.3bn RNA deal Image: Primary
Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3bn, adding an RNA interference platform and investigational medicines to its pipeline. The transaction has unanimous approval from Silence's board and would be funded through new debt using a UK scheme of arrangement. The acquisition includes divesiran, a treatment designed to silence a gene involved in iron regulation for patients with polycythaemia vera, a rare blood cancer. It is considered ready to progress into Phase III development. Closing is expected in the first quarter of 2027, subject to customary conditions; further clinical development must establish the treatment's safety and efficacy.
Sources
manufacturingchemist
Published by Tech & Business, a media brand covering technology and business. This story was sourced from manufacturingchemist and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Products Infrastructure
Products Infrastructure

JPMorgan deploys $230 billion in economic security financing

JPMorgan Chase deployed $230 billion of capital in the first year of its decade-long US economic security effort, Bloomberg reports. The financing includes equity and debt across areas including energy independence, defense and ae...

Bloomberg Technology
AI Capital
AI Capital

Tenstorrent raises $1.5 billion at $6.2 billion valuation

AI chip startup Tenstorrent has raised $1.5 billion in a funding round that values the company at $6.2 billion, according to a statement provided to Bloomberg News. The financing follows takeover interest in the company earlier th...

Bloomberg Technology
Capital AI
Capital AI

Town raises $108m at $1bn valuation for workplace AI assistants

Town announced a $108m Series B on Monday at a $1bn valuation, co-led by Forerunner Ventures and Menlo Ventures. Existing investors a16z and First Round Capital also participated. The startup connects individual AI assistants to ...

The Next Web
Capital Science
Capital Science

Nouscom closes €120 million financing for cancer vaccine trial

Swiss biotech Nouscom has closed a €120 million ($135 million) Series D financing to take its NOUS-209 cancer vaccine through a pivotal clinical trial, pharmaphorum reported. M Ventures and Revelation Partners led the round, with ...

pharmaphorum
Capital
Capital

Even Healthcare raises $50 million to expand Bengaluru hospitals

Even Healthcare has raised $50 million in an all-equity Series B led by Khosla Ventures, with participation from Alpha Wave, TechCrunch reports. The Indian startup says the round values it at $300 million, triple its valuation 18 ...

TechCrunch
Infrastructure Products
Infrastructure Products

PLD Space begins system-level testing of Miura 5 orbital rocket

PLD Space says it has begun system-level testing of its Miura 5 orbital rocket, with a fully assembled second stage at its Teruel test site in Spain. The stage will undergo a practice countdown using real propellants, followed by ...

The Next Web